Travere Therapeutics (TVTX) Stock Chart & Stock Price History $21.98 -1.60 (-6.79%) Closing price 04:00 PM EasternExtended Trading$22.26 +0.27 (+1.25%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Travere Therapeutics Stock Price Performance 5 Day Performance-3.14%1 Month Performance+14.03%3 Month Performance+20.51%6 Month Performance+155.36%Year-To-Date Performance+27.39%1 Year Performance+181.61% Receive TVTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Stock Chart for Friday, February, 21, 2025 TVTX Chart by TradingView Travere Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization02/20/2025$23.33$23.58+1.07%$23.69$23.141.33 million shs$1.84 billion02/19/2025$22.66$23.33+2.96%$23.46$22.501.54 million shs$1.82 billion02/18/2025$22.91$22.66-1.09%$23.33$22.481.41 million shs$1.77 billion02/17/2025$22.91$22.91$24.14$22.821.47 million shs$1.79 billion02/14/2025$23.72$22.91-3.41%$24.14$22.821.47 million shs$1.79 billion02/13/2025$23.20$23.72+2.24%$24.13$22.871.86 million shs$1.85 billion02/12/2025$23.75$23.20-2.32%$24.28$22.622.79 million shs$1.81 billion02/11/2025$21.10$23.75+12.56%$25.29$23.016.41 million shs$1.85 billion02/10/2025$21.75$21.10-2.99%$21.68$20.281.80 million shs$1.65 billion02/07/2025$21.86$21.75-0.50%$22.25$21.492.44 million shs$1.70 billion Get the Latest News and Ratings for TVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 02/06/2025$21.21$21.86+3.06%$22.13$21.272.54 million shs$1.71 billion02/05/2025$21.10$21.21+0.52%$21.86$20.671.47 million shs$1.66 billion02/04/2025$20.22$21.10+4.35%$21.20$20.06987,233 shs$1.65 billion02/03/2025$20.46$20.22-1.17%$20.57$19.671.22 million shs$1.58 billion01/31/2025$21.05$20.46-2.80%$21.40$20.331.14 million shs$1.60 billion01/30/2025$20.45$21.05+2.93%$21.24$20.491.04 million shs$1.64 billion01/29/2025$21.07$20.45-2.93%$21.32$19.781.09 million shs$1.60 billion01/28/2025$20.13$21.07+4.65%$21.37$19.891.34 million shs$1.64 billion01/27/2025$20.31$20.13-0.89%$20.73$19.77779,440 shs$1.57 billion01/24/2025$20.81$20.31-2.40%$21.56$20.261.27 million shs$1.59 billion01/23/2025$19.46$20.81+6.94%$20.89$18.972.03 million shs$1.62 billion01/22/2025$19.46$19.46$19.69$18.531.88 million shs$1.52 billion01/21/2025$18.37$19.46+5.93%$19.76$18.511.96 million shs$1.52 billion01/20/2025$18.37$18.37$18.74$18.24879,442 shs$1.43 billion Related Companies Legend Biotech Stock Chart Axsome Therapeutics Stock Chart Telix Pharmaceuticals Limited American Depositary Shares Stock Chart Lantheus Stock Chart BridgeBio Pharma Stock Chart Nuvalent Stock Chart Elanco Animal Health Stock Chart TG Therapeutics Stock Chart Cytokinetics Stock Chart Grifols Stock Chart Receive TVTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:TVTX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
